此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Zinc and Inflammation in Sepsis

2013年7月4日 更新者:University of Aberdeen

The purpose of the proposed project is to investigate measures of zinc status in relation to oxidative stress and inflammation in patients with sepsis. We hypothesise that zinc depletion can modulate inflammatory responses, leading to increased oxidative stress and mitochondrial dysfunction.

Sepsis is a severe infection is the leading cause of death in critically ill patients [1]. Zinc deficiency impairs overall immune function and resistance to infection [2]. In vitro exposure of monocytes to lipopolysaccharide (LPS) leads to decreased cellular zinc content [3] and zinc redistribution has been shown in human volunteers in response to LPS [4]. Zinc depletion occurs in hospitalized patients including those with infections, the elderly, alcoholics, trauma or burns [5-8], conditions which are common among critically ill patients with sepsis. In a mouse model of sepsis, zinc depletion prior to sepsis resulted in more inflammation and more severe organ injury and increased mortality [9]. In patients with sepsis, early feeding with zinc resulted in faster recovery of organ function compared with control [10]. Zinc status is likely to be compromised in the critically ill and that zinc depletion may affect inflammatory responses and recovery.

Although zinc is not an antioxidant itself, it binds to metallothionein [11] and zinc supplementation decreases oxidative stress [12]. Oxidative stress has been consistently reported in patients with sepsis [13-15]. We have recently shown that protection of mitochondrial function with antioxidants can reduce organ damage in rats [16]. Pentraxin-3 is an inflammatory marker which is regulated in part by antioxidants and plays a key role in innate immunity [17].

The consequences of zinc deficiency may relate, in part, to its effects on nuclear factor NFκB, a transcription factor crucial to the signalling networks involved in sepsis [18]. Higher NFκB activity is associated with increased mortality in patients with sepsis [19,20]. It is likely that compromised antioxidant defences and inflammation occurs as a consequence of zinc deficiency.

We propose to measure plasma zinc and metallothionein mRNA status in relation to inflammatory markers including key cytokines, pentraxin-3, markers of oxidative stress and antioxidant status in patients with sepsis.

研究概览

地位

完全的

条件

详细说明

Following ethical approval consent will be sought from either the patient, or assent from a near relative. Successive patients admitted to the Intensive Care Unit at Aberdeen Royal Infirmary who fulfil the following criteria for sepsis, given below, within a 24h time window, will be included.

  • Clinical suspicion or evidence of acute infection
  • SIRS defined by two or more of the following:

    1. Core temperature <36 degrees C or >38 degrees C
    2. Tachycardia; heart rate > 90 beats/min.
    3. Tachypnoea; respiratory rate > 20 breaths/min or mechanical ventilation
    4. White blood count >12 x 109/l or <4 x 109/l

In this pilot study we will recruit 20 patients with sepsis and 20 critically ill patients with no clinical suspicion of sepsis. Patients will be excluded if they are <16 years, pregnant or lactating, HIV positive, receiving corticosteroids or other known immuno-modulatory drugs (including statins), have cancer or autoimmune disorders or if consent/assent is refused.

Blood samples will be obtained on Days 1,2, 5, 10 and 14 of the ICU stay. Peripheral whole blood will be sampled from an indwelling arterial line and plasma will be separated for analysis of plasma zinc using atomic absorption spectroscopy. Plasma interleukin-6 (IL-6) and pentraxin-3 (PTX3) will be measured using enzyme immunoassay and total antioxidant capacity and lipid hydroperoxides will be measured colourimetrically [17]. Peripheral blood mononuclear cells (MNC) will be separated using single density gradient centrifugation, RNA extracted and metallothionein mRNA measured using qPCR [21]. Nuclear extracts of MNC will be prepared and nuclear factor kappa B (NFκB)activation measured using an enzyme immunoassay [17].

研究类型

观察性的

注册 (实际的)

39

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Scotland
      • Aberdeen、Scotland、英国、AB41 8TK
        • Aberdeen Royal Infirmary

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

16年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Successive patients admitted to the Intensive Care Unit at Aberdeen Royal Infirmary who fulfil the following criteria for sepsis, given below, within a 24h time window.

• .

描述

Patients with sepsis

Inclusion Criteria:

  • admitted to ICU with clinical suspicion or evidence of acute infection PLUS two or more of the following:

    1. Core temperature <36 degrees C or >38 degrees C
    2. Tachycardia; heart rate > 90 beats/min.
    3. Tachypnoea; respiratory rate > 20 breaths/min or mechanical ventilation
    4. White blood count >12 x 10 9/l or <4 x 10 9/l

      Control patients

  • admitted to ICU with no clinical evidence or suspicion of infection

Exclusion Criteria:

  • under 16 years old
  • pregnant or lactating
  • HIV positive
  • receiving corticosteroids or other known immuno-modulatory drugs
  • treated with statins in the last month
  • have cancer
  • have autoimmune disorders
  • consent/assent is refused

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:病例对照
  • 时间观点:预期

队列和干预

团体/队列
败血症
败血症患者
Control
Patients with no clinical evidence of sepsis, but who are critically ill

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Plasma zinc concentration
大体时间:14 days
Plasma zinc will be measured in patients with sepsis and non-spetic critically ill control patients.
14 days

次要结果测量

结果测量
措施说明
大体时间
Interleukin-6
大体时间:14 days
The relationship between IL-6 and plasma zinc
14 days
Pentraxin-3
大体时间:14 days
The relationship between PTX-3 and plasma zinc
14 days
Plasma lipid peroxide
大体时间:14 days
The relationship between LPO and plasma zinc
14 days
Plasma total antioxidant capacity
大体时间:14 days
The relationship between TAC and plasma zinc
14 days
Metallothionein mRNA
大体时间:14 days
Change in MTmRNA in mononuclear leucocytes in relation to plasma zinc and inflammatory markers
14 days
Nuclear factor kappa B
大体时间:14 days
Change in NFkB in nuclear extracts from mononuclear cells in relation to plasma zinc
14 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Helen Galley, PhD、University of Aberdeen
  • 首席研究员:Nigel Webster, PhD、University of Aberdeen

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2012年1月1日

初级完成 (实际的)

2013年5月1日

研究完成 (实际的)

2013年5月1日

研究注册日期

首次提交

2011年3月31日

首先提交符合 QC 标准的

2011年3月31日

首次发布 (估计)

2011年4月4日

研究记录更新

最后更新发布 (估计)

2013年7月8日

上次提交的符合 QC 标准的更新

2013年7月4日

最后验证

2013年7月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • 11/AL/0137

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅